Skip to main content
Triangle logo TriangleGet started

Carboplatin (NCT04892953)

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy: a one-minute explainerNCT048929531 min

Carboplatin trial for Stage III Lung Cancer AJCC v8 (NCT04892953). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults whose originally stage III non-small-cell lung cancer persisted or progressed after chemoradiation and durvalumab. Early progression and certain targetable mutations exclude participation.

The idea: radiation and/or surgery treats selected lesions, followed by intravenous durvalumab to release an immune brake. Patients with more than three progressing lesions also receive chemotherapy. Researchers measure time without further progression. Patients must be suitable for radiation to at least one lesion.

This phase 2 study plans 51 patients. Joe Chang leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.